methods. Mass ESI-HMRS measurements were also performed. Furthermore, these compounds were screened for their in vitro cytotoxicity activities against three cancer cell lines; namely, those of the liver (line HepG2), prostate (line DU145) and breast (line MBA-MB-231). The cytotoxicity assessment revealed that compounds 5d, 5g, 5h and 5i exhibit promising antiproliferative effects (IC50 1–5 µM) against
在碱性介质中,通过
查耳酮 (4a-i) 与
丙二腈的缩合,成功合成了一系列带有
2-甲氧基吡啶-3-甲腈 (5a-i) 的芳基取代基,收率良好。在大多数情况下,缩合过程提供了获得各种甲氧基
吡啶衍生物(6a-g)作为低产率副产物的途径。所有新化合物都使用不同的光谱方法进行了充分表征。还进行了质量 ESI-HMRS 测量。此外,还筛选了这些化合物对三种癌
细胞系的体外细胞毒性活性;即肝脏(HepG2系)、前列腺(DU145系)和乳腺(MBA-MB-231系)的那些。细胞毒性评估表明,化合物 5d、5g、5h 和 5i 对这三种癌
细胞系表现出有希望的抗增殖作用(IC50 1-5 µM)。